GangaGen Secures Additional US$7.9M from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Klebsiella pneumoniae

New funding will help tackle multidrug-resistant Klebsiella pneumoniae. BANGALORE, India, Dec. 19, 2024 /PRNewswire/ -- GangaGen is pleased to announce today that it has secured the third installment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria...